|
1
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Aggarwal BB: Nuclear factor-kappaB: The
enemy within. Cancer Cell. 6:203–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kuper H, Adami HO and Trichopoulos D:
Infections as a major preventable cause of human cancer. J Intern
Med. 248:171–183. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Balkwill F: TNF-alpha in promotion and
progression of cancer. Cancer Metastasis Rev. 25:409–416. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fang WB, Yao M, Brummer G, Acevedo D,
Alhakamy N, Berkland C and Cheng N: Targeted gene silencing of CCL2
inhibits triple negative breast cancer progression by blocking
cancer stem cell renewal and M2 macrophage recruitment. Oncotarget.
7:49349–49367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Niemeier LA, Dabbs DJ, Beriwal S, Striebel
JM and Bhargava R: Androgen receptor in breast cancer: Expression
in estrogen receptor-positive tumors and in estrogen
receptor-negative tumors with apocrine differentiation. Mod Pathol.
23:205–212. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Anders CK and Carey LA: Biology,
metastatic patterns, and treatment of patients with triple-negative
breast cancer. Clin Breast Cancer. 2 (Suppl 2):S73–S81. 2009.
View Article : Google Scholar
|
|
10
|
Albain KS, Unger JM, Crowley JJ, Coltman
CA Jr and Hershman DL: Racial disparities in cancer survival among
randomized clinical trials patients of the Southwest oncology
group. J Natl Cancer Inst. 101:984–992. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beaumont T and Leadbeater M: Treatment and
care of patients with metastatic breast cancer. Nurs Stand.
25:49–56. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez Y, Cueva J, Palomo AG, Ramos M,
de Juan A, Calvo L, García-Mata J, García-Teijido P, Peláez I and
García-Estévez L: Novel therapeutic approaches to the treatment of
metastatic breast cancer. Cancer Treat Rev. 36:33–42. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu P, Kumar IS, Brown S, Kannappan V,
Tawari PE, Tang JZ, Jiang W, Armesilla AL, Darling JL and Wang W:
Disulfiram targets cancer stem-like cells and reverses resistance
and cross-resistance in acquired paclitaxel-resistant
triple-negative breast cancer cells. Br J Cancer. 109:1876–1885.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Craig DW, O'Shaughnessy JA, Kiefer JA,
Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A,
Blum JL, et al: Genome and transcriptome sequencing in prospective
metastatic triple-negative breast cancer uncovers therapeutic
vulnerabilities. Mol Cancer Ther. 12:104–116. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Allavena P, Garlanda C, Borrello MG, Sica
A and Mantovani A: Pathways connecting inflammation and cancer.
Curr Opin Genet Dev. 18:3–10. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Candido J and Hagemann T: Cancer-related
inflammation. J Clin Immunol. 33 (Suppl 1):S79–S84. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saji H, Koike M, Yamori T, Saji S, Seiki
M, Matsushima K and Toi M: Significant correlation of monocyte
chemoattractant protein-1 expression with neovascularization and
progression of breast carcinoma. Cancer. 92:1085–1091. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bieche I, Chavey C, Andrieu C, Busson M,
Vacher S, Corre LL, Guinebretière JM, Burlinchon S, Lidereau R and
Lazennec G: CXC chemokines located in the 4q21 region are
up-regulated in breast cancer. Endocr Relat Cancer. 14:1039–1052.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang WB, Jokar I, Zou A, Lambert D,
Dendukuri P and Cheng N: CCL2/CCR2 chemokine signaling coordinates
survival and motility of breast cancer cells through Smad3 protein-
and p42/44 mitogen-activated protein kinase (MAPK)-dependent
mechanisms. J Biol Chem. 287:36593–36608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Perrot-Applanat M, Vacher S, Toullec A,
Pelaez I, Velasco G, Cormier F, El Sheikh Saad H, Lidereau R, Baud
V and Bièche I: Similar NF-kB gene signatures in TNF-α treated
human endothelial cells and breast tumor biopsies. PLoS One.
6:e215892011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leek RD, Landers R, Fox SB, Ng F, Harris
AL and Lewis CE: Association of tumour necrosis factor alpha and
its receptors with thymidine phosphorylase expression in invasive
breast carcinoma. Br J Cancer. 77:2246–2251. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang N, Liang H and Zen K: Molecular
mechanisms that influence the macrophage m1-m2 polarization
balance. Front Immunol. 5:6142014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yin Y, Chen X and Shu Y: Gene expression
of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed
Pharmacother. 63:421–428. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Voss V, Senft C, Lang V, Ronellenfitsch
MW, Steinbach JP, Seifert V and Kögel D: The pan-Bcl-2 inhibitor
(−)-gossypol triggers autophagic cell death in malignant glioma.
Mol Cancer Res. 8:1002–1016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dreesen O and Brivanlou AH: Signaling
pathways in cancer and embryonic stem cells. Stem Cell Rev. 3:7–17.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zubair A and Frieri M: Role of nuclear
factor-kB in breast and colorectal cancer. Curr Allergy Asthma Rep.
13:44–49. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhong S, Leong J, Ye W, Xu P, Lin SH, Liu
JY and Lin YC: (−)-Gossypol-enriched cottonseed oil inhibits
proliferation and adipogenesis of human breast pre-adipocytes.
Anticancer Res. 33:949–955. 2013.PubMed/NCBI
|
|
29
|
Cao H, Sethumadhavan K and Bland JM:
Isolation of cottonseed extracts that affect human cancer cell
growth. Sci Rep. 8:104582018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He Z, Zhang H and Olk DC: Chemical
composition of defatted cottonseed and soy meal products. PLoS One.
10:e01299332015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sharifi-Rad M, Fokou PVT, Sharopov F,
Martorell M, Ademiluyi AO, Rajkovic J, Salehi B, Martins N, Iriti M
and Sharifi-Rad J: Antiulcer agents: From plant extracts to
phytochemicals in healing promotion. Molecules. 23:17512018.
View Article : Google Scholar
|
|
32
|
Wang X, Howell CP, Chen F, Yin J and Jiang
Y: Gossypol-a polyphenolic compound from cotton plant. Adv Food
Nutr Res. 58:215–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B,
Roller PP, Wang S and Yang D: Molecular mechanism of
gossypol-induced cell growth inhibition and cell death of HT-29
human colon carcinoma cells. Biochem Pharmacol. 66:93–103. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pang X, Wu Y, Wu Y, Lu B, Chen J, Wang J,
Yi Z, Qu W and Liu M: (−)-Gossypol suppresses the growth of human
prostate cancer xenografts via modulating VEGF signaling-mediated
angiogenesis. Mol Cancer Ther. 10:795–805. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Flack MR, Pyle RG, Mullen NM, Lorenzo B,
Wu YW, Knazek RA, Nisula BC and Reidenberg MM: Oral gossypol in the
treatment of metastatic adrenal cancer. J Clin Endocrinol Metab.
76:1019–1024. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Moon DO, Kim MO, Lee JD and Kim GY:
Gossypol suppresses NF-kappaB activity and NF-kappaB-related gene
expression in human leukemia U937 cells. Cancer Lett. 264:192–200.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Benvenuto M, Mattera R, Masuelli L,
Taffera G, Andracchio O, Tresoldi I, Lido P, Giganti MG, Godos J,
Modesti A and Bei R: (±)-Gossypol induces apoptosis and autophagy
in head and neck carcinoma cell lines and inhibits the growth of
transplanted salivary gland cancer cells in BALB/c mice. Int J Food
Sci Nutr. 68:298–312. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moon DO, Choi YH, Moon SK, Kim WJ and Kim
GY: Gossypol decreases tumor necrosis factor-α-induced
intercellular adhesion molecule-1 expression via suppression of
NF-κB activity. Food Chem Toxicol. 49:999–1005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gilbert NE, O'Reilly JE, Chang CJ, Lin YC
and Brueggemeier RW: Antiproliferative activity of gossypol and
gossypolone on human breast cancer cells. Life Sci. 57:61–67. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hu YF, Chang CJ, Brueggemeier RW and Lin
YC: Gossypol inhibits basal and estrogen-stimulated DNA synthesis
in human breast carcinoma cells. Life Sci. 53:PL433–PL438. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yoshida R, Niki M, Jyotaki M, Sanematsu K,
Shigemura N and Ninomiya Y: Modulation of sweet responses of taste
receptor cells. Semin Cell Dev Biol. 24:226–231. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cheng W, Zhao YQ, Li YM and Yang DJ:
Effects of gossypol acetate on apoptosis in primary cultured cells
from patients with lymphoid leukemia and its synergy with
dexamethasone. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 20:229–234.
2012.(In Chinese). PubMed/NCBI
|
|
44
|
Baoleri X, Dong C, Zhou Y, Zhang Z, Lu X,
Xie P and Li Y: Combination of L-gossypol and low-concentration
doxorubicin induces apoptosis in human synovial sarcoma cells. Mol
Med Rep. 12:5924–5932. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Karaca B, Atmaca H, Uzunoglu S, Karabulut
B, Sanli UA and Uslu R: Enhancement of taxane-induced cytotoxicity
and apoptosis by gossypol in human breast cancer cell line MCF-7. J
BUON. 14:479–485. 2009.PubMed/NCBI
|
|
46
|
Zhao GX, Xu LH, Pan H, Lin QR, Huang MY,
Cai JY, Ouyang DY and He XH: The BH3-mimetic gossypol and
noncytotoxic doses of valproic acid induce apoptosis by suppressing
cyclin-A2/Akt/FOXO3a signaling. Oncotarget. 6:38952–38966. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tate CR, Rhodes LV, Segar HC, Driver JL,
Pounder FN, Burow ME and Collins-Burow BM: Targeting
triple-negative breast cancer cells with the histone deacetylase
inhibitor panobinostat. Breast Cancer Res. 14:R792012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sato N, Beitz JG, Kato J, Yamamoto M,
Clark JW, Calabresi P, Raymond A and Frackelton Jr AR:
Platelet-derived growth factor indirectly stimulates angiogenesis
in vitro. Am J Pathol. 142:1119–1130. 1993.PubMed/NCBI
|
|
49
|
Messeha SS, Zarmouh NO, Mendonca P,
Alwagdani H, Kolta MG and Soliman KFA: The inhibitory effects of
plumbagin on the NF-kB pathway and CCL2 release in racially
different triple-negative breast cancer cells. PLoS One.
13:e02011162018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yamamoto H, Omelchenko I, Shi X and
Nuttall AL: The influence of NF-kappaB signal-transduction pathways
on the murine inner ear by acoustic overstimulation. J Neurosci
Res. 87:1832–1840. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gallelli L, Falcone D, Cannataro R, Perri
M, Serra R, Pelaia G, Maselli R, Savino R, Spaziano G and
D'Agostino B: Theophylline action on primary human bronchial
epithelial cells under proinflammatory stimuli and steroidal drugs:
A therapeutic rationale approach. Drug Des Dev Ther. 11:265–272.
2017. View Article : Google Scholar
|
|
53
|
Barba-Barajas M, Hernandez-Flores G,
Lerma-Diaz JM, Ortiz-Lazareno PC, Domínguez-Rodríguez JR,
Barba-Barajas L, de Celis R, Jave-Suarez LF, Aguilar-Lemarroy AC,
Guevara-Barraza MG and Bravo-Cuellar A: Gossypol induced apoptosis
of polymorphonuclear leukocytes and monocytes: Involvement of
mitochondrial pathway and reactive oxygen species. Immunopharmacol
Immunotoxicol. 31:320–330. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Anderson GM, Nakada MT and DeWitte M:
Tumor necrosis factor-alpha in the pathogenesis and treatment of
cancer. Curr Opin Pharmacol. 4:314–320. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ma Y, Ren Y, Dai ZJ, Wu CJ, Ji YH and Xu
J: IL-6, IL-8 and TNF-α levels correlate with disease stage in
breast cancer patients. Adv Clin Exp Med. 26:421–426. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
John M, Au BT, Jose PJ, Lim S, Saunders M,
Barnes PJ, Mitchell JA, Belvisi MG and Chung KF: Expression and
release of interleukin-8 by human airway smooth muscle cells:
Inhibition by Th-2 cytokines and corticosteroids. Am J Respir Cell
Mol Biol. 18:84–90. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Grund EM, Kagan D, Tran CA, Zeitvogel A,
Starzinski-Powitz A, Nataraja S and Palmer SS: Tumor necrosis
factor-alpha regulates inflammatory and mesenchymal responses via
mitogen-activated protein kinase kinase, p38, and nuclear factor
kappaB in human endometriotic epithelial cells. Mol Pharmacol.
73:1394–1404. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
An J, Xue Y, Long M, Zhang G, Zhang J and
Su H: Targeting CCR2 with its antagonist suppresses viability,
motility and invasion by downregulating MMP-9 expression in
non-small cell lung cancer cells. Oncotarget. 8:39230–39240. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Strieter RM, Wiggins R, Phan SH, Wharram
BL, Showell HJ, Remick DC, Chensue SW and Kunkel SL: Monocyte
chemotactic protein gene expression by cytokine-treated human
fibroblasts and endothelial cells. Biochem Biophys Res Commun.
162:694–700. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Sticherling M, Hetzel F, Schroder JM and
Christophers E: Time- and stimulus-dependent secretion of
NAP-1/IL-8 by human fibroblasts and endothelial cells. J Invest
Dermatol. 101:573–576. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zachariae CO, Anderson AO, Thompson HL,
Appella E, Mantovani A, Oppenheim JJ and Matsushima K: Properties
of monocyte chemotactic and activating factor (MCAF) purified from
a human fibrosarcoma cell line. J Exp Med. 171:2177–2182. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Krupa A, Fol M, Dziadek BR, Kepka E,
Wojciechowska D, Brzostek A, Torzewska A, Dziadek J, Baughman RP,
Griffith D and Kurdowska AK: Binding of CXCL8/IL-8 to mycobacterium
tuberculosis modulates the innate immune response. Mediators
Inflamm. 2015:1247622015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ueno T, Toi M, Saji H, Muta M, Bando H,
Kuroi K, Koike M, Inadera H and Matsushima K: Significance of
macrophage chemoattractant protein-1 in macrophage recruitment,
angiogenesis, and survival in human breast cancer. Clin Cancer Res.
6:3282–3289. 2000.PubMed/NCBI
|
|
64
|
Matsushima K, Larsen CG, DuBois GC and
Oppenheim JJ: Purification and characterization of a novel monocyte
chemotactic and activating factor produced by a human
myelomonocytic cell line. J Exp Med. 169:1485–1490. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Espinoza-Sanchez NA, Chimal-Ramirez GK,
Mantilla A and Fuentes-Panana EM: IL-1β, IL-8, and matrix
metalloproteinases-1,-2, and −10 are enriched upon monocyte-breast
cancer cell cocultivation in a matrigel-based three-dimensional
system. Front Immunol. 8:2052017. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Nam JS, Kang MJ, Suchar AM, Shimamura T,
Kohn EA, Michalowska AM, Jordan VC, Hirohashi S and Wakefield LM:
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of
dysadherin in human breast cancer cells. Cancer Res. 66:7176–7184.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Tsuyada A, Chow A, Wu J, Somlo G, Chu P,
Loera S, Luu T, Li XA, Wu X, Ye W, et al: CCL2 mediates cross-talk
between cancer cells and stromal fibroblasts that regulates breast
cancer stem cells. Cancer Res. 72:2768–2779. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Koury J, Zhong L and Hao J: Targeting
signaling pathways in cancer stem cells for cancer treatment. Stem
Cells Int. 2017:29258692017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Pires BR, DE Amorim ÍS, Souza LD,
Rodrigues JA and Mencalha AL: Targeting cellular signaling pathways
in breast cancer stem cells and its implication for cancer
treatment. Anticancer Res. 36:5681–5691. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Huth HW, Santos DM, Gravina HD, Resende
JM, Goes AM, de Lima ME and Ropert C: Upregulation of p38 pathway
accelerates proliferation and migration of MDA-MB-231 breast cancer
cells. Oncol Rep. 37:2497–2505. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Peters RT, Liao SM and Maniatis T:
IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex.
Mol Cell. 5:513–522. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Bauer D, Redmon N, Mazzio E and Soliman
KF: Apigenin inhibits TNFα/IL-1α-induced CCL2 release through
IKBK-epsilon signaling in MDA-MB-231 human breast cancer cells.
PLoS One. 12:e01755582017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Williams V, Grosset AA, Zamorano Cuervo N,
St-Pierre Y, Sylvestre MP, Gaboury L and Grandvaux N: Detection of
IKKepsilon by immunohistochemistry in primary breast cancer:
Association with EGFR expression and absence of lymph node
metastasis. BMC Cancer. 17:3562017. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Guo JP, Shu SK, Esposito NN, Coppola D,
Koomen JM and Cheng JQ: IKK phosphorylation of estrogen receptor α
Ser-167 and contribution to tamoxifen resistance in breast cancer.
J Biol Chem. 291:228572016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Berishaj M, Gao SP, Ahmed S, Leslie K,
Al-Ahmadie H, Gerald WL, Bornmann W and Bromberg JF: Stat3 is
tyrosine-phosphorylated through the interleukin-6/glycoprotein
130/Janus kinase pathway in breast cancer. Breast Cancer Res.
9:R322007. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li L and Shaw PE: Autocrine-mediated
activation of STAT3 correlates with cell proliferation in breast
carcinoma lines. J Biol Chem. 277:17397–17405. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Walker SR, Nelson EA, Zou L, Chaudhury M,
Signoretti S, Richardson A and Frank DA: Reciprocal effects of
STAT5 and STAT3 in breast cancer. Mol Cancer Res. 7:966–976. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44(+)CD24(−) stem cell-like breast
cancer cells in human tumors. J Clin Invest. 121:2723–2735. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
House CD, Grajales V, Ozaki M, Jordan E,
Wubneh H, Kimble DC, James JM, Kim MK and Annunziata CM: IΚΚε
cooperates with either MEK or non-canonical NF-kB driving growth of
triple-negative breast cancer cells in different contexts. BMC
Cancer. 18:5952018. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Boehm JS, Zhao JJ, Yao J, Kim SY,
Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S,
Richardson AL, et al: Integrative genomic approaches identify IKBKE
as a breast cancer oncogene. Cell. 129:1065–1079. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Hutti JE, Shen RR, Abbott DW, Zhou AY,
Sprott KM, Asara JM, Hahn WC and Cantley LC: Phosphorylation of the
tumor suppressor CYLD by the breast cancer oncogene IKKepsilon
promotes cell transformation. Mol Cell. 34:461–472. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Barbie TU, Alexe G, Aref AR, Li S, Zhu Z,
Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M, et al: Targeting an
IKBKE cytokine network impairs triple-negative breast cancer
growth. J Clin Invest. 124:5411–5423. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Qin B and Cheng K: Silencing of the IKKε
gene by siRNA inhibits invasiveness and growth of breast cancer
cells. Breast Cancer Res. 12:R742010. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Bartholomeusz C, Gonzalez-Angulo AM, Liu
P, Hayashi N, Lluch A, Ferrer-Lozano J and Hortobágyi GN: High ERK
protein expression levels correlate with shorter survival in
triple-negative breast cancer patients. Oncologist. 17:766–774.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Seddighzadeh M, Zhou JN, Kronenwett U,
Shoshan MC, Auer G, Sten-Linder M, Wiman B and Linder S: ERK
signalling in metastatic human MDA-MB-231 breast carcinoma cells is
adapted to obtain high urokinase expression and rapid cell
proliferation. Clin Exp Metastasis. 17:649–654. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kyriakis JM and Avruch J: Mammalian MAPK
signal transduction pathways activated by stress and inflammation:
A 10-year update. Physiol Rev. 92:689–737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Cargnello M and Roux PP: Activation and
function of the MAPKs and their substrates, the MAPK-activated
protein kinases. Microbiol Mol Biol Rev. 75:50–83. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Samatar AA and Poulikakos PI: Targeting
RAS-ERK signalling in cancer: Promises and challenges. Nat Rev Drug
Discov. 13:928–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wen S, Hou Y, Fu L, Xi L, Yang D, Zhao M,
Qin Y, Sun K, Teng Y and Liu M: Cancer-associated fibroblast
(CAF)-derived IL32 promotes breast cancer cell invasion and
metastasis via integrin β3-p38 MAPK signalling. Cancer Lett.
442:320–332. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Liu Q, Li A, Tian Y, Wu JD, Liu Y, Li T,
Chen Y, Han X and Wu K: The CXCL8-CXCR1/2 pathways in cancer.
Cytokine Growth Factor Rev. 31:61–71. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Benoy IH, Salgado R, Van Dam P, Geboers K,
Van Marck E, Scharpé S, Vermeulen PB and Dirix LY: Increased serum
interleukin-8 in patients with early and metastatic breast cancer
correlates with early dissemination and survival. Clin Cancer Res.
10:7157–7162. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Guo Y, Zang Y, Lv L, Cai F, Qian T, Zhang
G and Feng Q: IL8 promotes proliferation and inhibition of
apoptosis via STAT3/AKT/NFkB pathway in prostate cancer. Mol Med
Rep. 16:9035–9042. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Snoussi K, Mahfoudh W, Bouaouina N, Ahmed
SB, Helal AN and Chouchane L: Genetic variation in IL-8 associated
with increased risk and poor prognosis of breast carcinoma. Hum
Immunol. 67:13–21. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zuccari DA, Leonel C, Castro R, Gelaleti
GB, Jardim BV, Moscheta MG, Regiani VR, Ferreira LC, Lopes JR, Neto
Dde S and Esteves JL: An immunohistochemical study of interleukin-8
(IL-8) in breast cancer. Acta Histochem. 114:571–576. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Kim S, Jeon M, Lee JE and Nam SJ: MEK
activity controls IL-8 expression in tamoxifen-resistant MCF-7
breast cancer cells. Oncol Rep. 35:2398–2404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kim S, You D, Jeong Y, Yu J, Kim SW, Nam
SJ and Lee JE: Berberine down-regulates IL-8 expression through
inhibition of the EGFR/MEK/ERK pathway in triple-negative breast
cancer cells. Phytomedicine. 50:43–49. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yao C, Lin Y, Chua MS, Ye CS, Bi J, Li W,
Zhu YF and Wang SM: Interleukin-8 modulates growth and invasiveness
of estrogen receptor-negative breast cancer cells. Int J Cancer.
121:1949–1957. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Park SH, Das BB, Casagrande F, Tian Y,
Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, Marassi FM
and Opella SJ: Structure of the chemokine receptor CXCR1 in
phospholipid bilayers. Nature. 491:779–783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Singh JK, Simoes BM, Clarke RB and Bundred
NJ: Targeting IL-8 signalling to inhibit breast cancer stem cell
activity. Expert Opin Ther Targets. 17:1235–1241. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Singh JK, Simoes BM, Howell SJ, Farnie G
and Clarke RB: Recent advances reveal IL-8 signaling as a potential
key to targeting breast cancer stem cells. Breast Cancer Res.
15:2102013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Alfaro C, Teijeira A, Onate C, Pérez G,
Sanmamed MF, Andueza MP, Alignani D, Labiano S, Azpilikueta A,
Rodriguez-Paulete A, et al: Tumor-produced interleukin-8 attracts
human myeloid-derived suppressor cells and elicits extrusion of
neutrophil extracellular traps (NETs). Clin Cancer Res.
22:3924–3936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Elliott CL, Allport VC, Loudon JA, Wu GD
and Bennett PR: Nuclear factor-kappa B is essential for
up-regulation of interleukin-8 expression in human amnion and
cervical epithelial cells. Mol Hum Reprod. 7:787–790. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wang L, Tang C, Cao H, Li K, Pang X, Zhong
L, Dang W, Tang H, Huang Y, Wei L, et al: Activation of IL-8 via
PI3K/Akt-dependent pathway is involved in leptin-mediated
epithelial-mesenchymal transition in human breast cancer cells.
Cancer Biol Ther. 16:1220–1230. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Lian S, Xia Y, Ung TT, Khoi PN, Yoon HJ,
Kim NH, Kim KK and Jung YD: Carbon monoxide releasing molecule-2
ameliorates IL-1β-induced IL-8 in human gastric cancer cells.
Toxicology 361–362. 24–38. 2016. View Article : Google Scholar
|
|
106
|
Singh RK, Gutman M, Radinsky R, Bucana CD
and Fidler IJ: Expression of interleukin 8 correlates with the
metastatic potential of human melanoma cells in nude mice. Cancer
Res. 54:3242–3247. 1994.PubMed/NCBI
|
|
107
|
Fernando RI, Hamilton DH, Dominguez C,
David JM, McCampbell KK and Palena C: IL-8 signaling is involved in
resistance of lung carcinoma cells to erlotinib. Oncotarget.
7:42031–42044. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Jiang P, Enomoto A, Jijiwa M, Kato T,
Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y and Takahashi M:
An actin-binding protein girdin regulates the motility of breast
cancer cells. Cancer Res. 68:1310–1318. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lin C, Ear J, Pavlova Y, Mittal Y,
Kufareva I, Ghassemian M, Abagyan R, Garcia-Marcos M and Ghosh P:
Tyrosine phosphorylation of the Gα-interacting protein GIV promotes
activation of phosphoinositide 3-kinase during cell migration. Sci
Signal. 4:ra642011. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ni W, Fang Y, Tong L, Tong Z, Yi F, Qiu J,
Wang R and Tong X: Girdin regulates the migration and invasion of
glioma cells via the PI3K-Akt signaling pathway. Mol Med Rep.
12:5086–5092. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Romashkova JA and Makarov SS: NF-kappaB is
a target of AKT in anti-apoptotic PDGF signalling. Nature.
401:86–90. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
112
|
Jiang BH and Liu LZ: PI3K/PTEN signaling
in tumorigenesis and angiogenesis. Biochim Biophys Acta.
1784:150–158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Abraham RT: Chemokine to the rescue:
Interleukin-8 mediates resistance to PI3K-pathway-targeted therapy
in breast cancer. Cancer Cell. 22:703–705. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Darnell JE: Validating Stat3 in cancer
therapy. Nat Med. 11:595–596. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Subramaniam A, Shanmugam MK, Perumal E, Li
F, Nachiyappan A, Dai X, Swamy SN, Ahn KS, Kumar AP, Tan BKH, et
al: Potential role of signal transducer and activator of
transcription (STAT)3 signaling pathway in inflammation, survival,
proliferation and invasion of hepatocellular carcinoma. Biochim
Biophys Acta. 1835:46–60. 2013.PubMed/NCBI
|
|
117
|
Rajendran P, Li F, Shanmugam MK, Kannaiyan
R, Goh JN, Wong KF, Wang W, Khin E, Tergaonkar V, Kumar AP, et al:
Celastrol suppresses growth and induces apoptosis of human
hepatocellular carcinoma through the modulation of STAT3/JAK2
signaling cascade in vitro and in vivo. Cancer Prev Res (Phila).
5:631–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Samson ME, Porter NG, Hurley DM, Adams SA
and Eberth JM: Disparities in breast cancer incidence, mortality,
and quality of care among African American and European American
women in South Carolina. South Med J. 109:24–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
